Literature DB >> 17517919

A structural basis for interferon-alpha-receptor interactions.

Jyothi Kumaran1, Lianhu Wei, Lakshmi P Kotra, Eleanor N Fish.   

Abstract

Interferon (IFN)-alpha subtypes exhibit differences in biological potencies based on their affinity interactions with the IFN receptor subunits, IFNAR1 and IFNAR2. Using available three-dimensional structural information and computational biology, homology models of human IFN-alpha1, human IFN-alpha8, IFN alfacon-1, and murine IFN-alpha4 were derived and docked with the extracellular region of human IFNAR2 to evaluate the behavior of potential interacting residue pairs and characterize the nature of the IFN-IFNAR2 binding interfaces. The data suggest that IFN afacon-1 has 9 optimal interactions with IFNAR2, comprising hydrophobic, electrostatic, and hydrogen bonding. Human IFN-alpha2 exhibits 8 optimal interactions, human IFN-alpha1, 7, and murine IFN-alpha4 exhibits the least number of optimal interactions, at 5. A model of IFNAR1 was generated, taking into consideration the IFNAR1 extracellular domain interaction with cell surface glycosphingolipids, putative ligand interaction residues, and residues stabilizing the structural integrity of IFNAR. IFNAR1 was then docked with the various IFN-IFNAR2 complexes to describe the complete extracellular receptor pocket with bound IFN. These data provide insights into the species specificity of IFN-alphas: residues in murine IFN-alpha4 that preclude strong affinity interactions with human IFNAR because of steric crowding and residues in human IFN-alpha8 that resemble a receptor interactive domain in murine IFN-alpha4, are described.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517919     DOI: 10.1096/fj.07-8585com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  13 in total

1.  Palmitoylation of interferon-alpha (IFN-alpha) receptor subunit IFNAR1 is required for the activation of Stat1 and Stat2 by IFN-alpha.

Authors:  Julie Claudinon; Pauline Gonnord; Emilie Beslard; Marta Marchetti; Keith Mitchell; Cédric Boularan; Ludger Johannes; Pierre Eid; Christophe Lamaze
Journal:  J Biol Chem       Date:  2009-06-26       Impact factor: 5.157

2.  O-linked glycosylation leads to decreased thermal stability of interferon alpha 2b as measured by two orthogonal techniques.

Authors:  Michael James Wilson Johnston; Grant Frahm; Xuguang Li; Yves Durocher; Mary Alice Hefford
Journal:  Pharm Res       Date:  2011-03-09       Impact factor: 4.200

3.  A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family.

Authors:  S Miersch; S Kuruganti; M R Walter; S S Sidhu
Journal:  Protein Eng Des Sel       Date:  2017-09-01       Impact factor: 1.650

4.  Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo.

Authors:  Kerry J Lavender; Kathrin Gibbert; Karin E Peterson; Erik Van Dis; Sandra Francois; Tyson Woods; Ronald J Messer; Ali Gawanbacht; Janis A Müller; Jan Münch; Katie Phillips; Brent Race; Michael S Harper; Kejun Guo; Eric J Lee; Mirko Trilling; Hartmut Hengel; Jacob Piehler; Jens Verheyen; Cara C Wilson; Mario L Santiago; Kim J Hasenkrug; Ulf Dittmer
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

5.  Age-related gene expression in Tourette syndrome.

Authors:  Lisa Lit; Amanda Enstrom; Frank R Sharp; Donald L Gilbert
Journal:  J Psychiatr Res       Date:  2008-05-15       Impact factor: 4.791

6.  The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types.

Authors:  Herwig P Moll; Thomas Maier; Anna Zommer; Thomas Lavoie; Christine Brostjan
Journal:  Cytokine       Date:  2010-10-12       Impact factor: 3.861

7.  Enhanced anti-HCV activity of interferon alpha 17 subtype.

Authors:  Aurelie Dubois; Catherine François; Veronique Descamps; Carole Fournier; Czeslaw Wychowski; Jean Dubuisson; Sandrine Castelain; Gilles Duverlie
Journal:  Virol J       Date:  2009-06-03       Impact factor: 4.099

8.  Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab.

Authors:  Vaheh Oganesyan; Li Peng; Robert M Woods; Herren Wu; William F Dall'Acqua
Journal:  J Biol Chem       Date:  2015-04-29       Impact factor: 5.157

9.  Characterization of the bovine type I IFN locus: rearrangements, expansions, and novel subfamilies.

Authors:  Angela M Walker; R Michael Roberts
Journal:  BMC Genomics       Date:  2009-04-24       Impact factor: 3.969

10.  Heterologous expression, immunochemical and computational analysis of recombinant human interferon alpha 2b.

Authors:  Iram Gull; Zahoor Qadir Samra; Muhammad Shahbaz Aslam; Muhammad Amin Athar
Journal:  Springerplus       Date:  2013-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.